AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.
Pharma & Biotech
Pharma & Biotech
AstraZeneca secures global rights to Jacobio Pharma’s Pan‑KRAS JAB‑23E73 in high‑stakes KRAS market expansion
Find out how Jacobio Pharma’s global licensing deal with AstraZeneca could reshape KRAS‑targeted cancer therapy development.